- URL: https://chineseantibody.org/webinar/
- Date: December 8th, Saturday, 9-10 pm, EST (December 9th, Sunday, 10-11 am, Beijing Time)
- Listed: December 10, 2018 1:20 pm
- Expires: This ad has expired
Time: December 8th, Saturday, 9-10 pm, EST (December 9th, Sunday, 10-11 am, Beijing Time)
Webinar abstract: G-protein coupled receptors (GPCRs) represent a class of molecules that are most frequently targeted for new drug development. More than 35% of currently marketed drugs act on one or more GPCRs. Accordingly, sales of these drugs constitute a considerable fraction of total drug sales. During 2011-2015, GPCR-targeted drugs generated $917 billion dollars of revenues. Despite the existence of large numbers of GPCR targets, not many GPCR-targeting antibody therapeutics are available in the market place today. This is largely due to the difficulties in generating and developing functional antibodies against GPCRs. More recently, however, efforts in development of anti-GPCR antibody therapeutics are gaining momentum. GMax is a biotechnology company with its main research lab based in Hangzhou, China. We are focusing on discovery and development of novel anti GPCR Mab therapeutics. Using our proprietary technology, we have developed a rich developmental pipeline filled with therapeutic antibodies and “bibodyies”. Some of these molecules have reached clinical or preclinical stages.
Speaker: Dr. Shuqian Jing
Dr. Jing founded Gmax Biopharm in 2010 as the company chairman and CEO. He has established a proprietary world class antibody platform targeting G-protein coupled receptors (GPCRs), aiming for the unmet medical needs in metabolic disorders, cardiovascular diseases and cancer. Gmax has built up a pipeline of GPCR MAbs and Bibodies for the treatments of diabetes, obesity, PAH, NASH and heart failure. Two of the pipeline antibodies are currently in clinical trials. 7 GPCR MAb/Bibodies are in preclinical development, 9 GPCR MAb/Bibodies are in early discovery. Prior to Gmax, Dr. Jing has almost 30 years of overseas working experiences both in the academic and biopharmaceutical industry. Besides the extensive contribution in drug discovery, he has also led more than 20 drug development projects at Amgen. Dr. Jing is a guest professor of Beijing Normal University and an honorary professor of Chinese Military Academy of Medical Sciences. He was also invited to lead and review seven Key State Healthcare Initiatives and Research Projects like 863, 973 and Mega-Innovation Programs. Dr. Jing is a recipient of Oversea Distinguished Young Scientist Award by China National Nature Science Foundation. He has published more than 40 scientific publications, including 5 Cell publications; and has filed more than 50 patents. Dr. Jing received his Ph.D from Salk Institute, San Diego in 1990.